NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
Rhea-AI Summary
NextCure (Nasdaq: NXTC) and Simcere announced that an abstract for SIM0505 (CDH6 ADC) was accepted for presentation at ASCO 2026, held May 29–June 2 in Chicago. SIM0505 is an investigational ADC targeting Cadherin-6 (CDH6) with a proprietary TOPOi payload.
The ongoing open-label Phase 1 study (NCT06792552) is evaluating SIM0505 in advanced solid tumors, including ovarian cancer, with emphasis on platinum-resistant ovarian cancer.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – NXTC
On the day this news was published, NXTC declined 1.40%, reflecting a mild negative market reaction. Argus tracked a peak move of +19.9% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $570K from the company's valuation, bringing the market cap to $40.16M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NXTC dipped 1.1% while close biotech peers showed mixed moves (e.g., BCTX up 9.55%, PRTG down 10.39%). Momentum peers APLM and BIVI also moved in opposite directions, pointing to a stock-specific reaction to the SIM0505 ASCO abstract.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Earnings & update | Positive | -2.9% | Full-year 2025 results and SIM0505/LNCB74 milestone and runway guidance. |
| Jan 23 | Pipeline update | Positive | -5.8% | Business update on SIM0505 and LNCB74 progress and preliminary cash position. |
| Nov 20 | Conference appearance | Neutral | -1.6% | Announcement of participation at Piper Sandler healthcare conference. |
| Nov 17 | PIPE financing | Positive | +2.7% | Closing of $21.5M PIPE to fund ADC proof-of-concept work. |
| Nov 12 | Private placement | Positive | +9.0% | Announcement of $21.5M private placement to extend cash runway into 2027. |
Recent positive updates and financings have produced mixed reactions, with some dilution events seeing positive moves but business updates often met with selling.
Over the past several months, NextCure has focused investors on its ADC pipeline and cash runway. In November 2025, the company announced a $21.5M private placement and related PIPE financing to extend runway into H1 2027, which saw generally positive price reactions. Subsequent business and earnings updates in January and March 2026, highlighting upcoming SIM0505 and LNCB74 milestones, were followed by negative moves. Today’s ASCO 2026 abstract acceptance for SIM0505 fits into this ongoing clinical execution narrative.
Regulatory & Risk Context
An effective shelf prospectus filed on 2025-11-26 registers 2,523,477 shares for resale by existing holders, consisting of outstanding shares and shares issuable on pre-funded warrants from the November 2025 financing. NextCure would only receive about $1,815 if all such pre-funded warrants are exercised, with no proceeds from subsequent resales.
Market Pulse Summary
This announcement highlights acceptance of a SIM0505 abstract for ASCO 2026, reinforcing NextCure’s focus on antibody‑drug conjugates in difficult cancers such as platinum‑resistant ovarian cancer. The study remains in Phase 1, so investors may track subsequent data presentations and trial updates rather than the abstract alone. Given prior financings and a resale shelf, attention to capital needs, upcoming SIM0505 proof‑of‑concept readouts, and broader biotech sentiment will remain important.
Key Terms
american society for clinical oncology medical
asco 2026 medical
antibody drug conjugate medical
adc medical
cadherin-6 medical
topoisomerase 1 inhibitor medical
open-label medical
platinum resistant ovarian cancer medical
AI-generated analysis. Not financial advice.
The American Society for Clinical Oncology to be held in Chicago May 29 – June 2, 2026
BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company, today announced that an abstract for SIM0505 has been accepted for the American Society for Clinical Oncology (ASCO 2026) meeting being held May 29 – June 2 in Chicago, Illinois. SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload.
The ongoing open-label, Phase 1 study (NCT06792552) is evaluating SIM0505 in advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer.
About SIM0505
SIM0505 is a novel antibody drug conjugate (ADC) directed to cadherin-6 (CDH6 ADC), featuring a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The ADC is designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. SIM0505 is being evaluated in an open-label, Phase 1 study (NCT06792552) for the potential treatment of advanced solid tumors, including ovarian cancer, with an emphasis on platinum resistant ovarian cancer. NextCure holds exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan which are retained by Simcere Zaiming Pharmaceutical Co., Ltd.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company focused on advancing innovative medicines to treat cancer patients through the use of targeted therapies including antibody-drug conjugates. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells within and beyond the tumor microenvironment, and the role each interaction plays in a biologic response.
About Simcere Zaiming
Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, "Simcere"). Founded in 2023, Simcere Zaiming is dedicated to developing groundbreaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including Enzeshu®, COSELA®, Enweida®, Endostar®, and Enlituo®. The Company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.
Forward-Looking Statements
Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “should”, “due”, “estimate”, “expect”, “intend”, “hope”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “seek”, “target”, “towards”, “forward”, “later”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.
Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: market and other conditions; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and not having any products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; NextCure’s reliance upon collaborators and international vendors for advancing clinical programs; NextCure’s ability to maintain listing of its common stock on the Nasdaq Global Select Market; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K and in NextCure’s other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
Mike Moyer
Managing Director,
LifeSci Advisors, LLC
Phone: (617) 308-4306
mmoyer@lifesciadvisors.com
